Literature DB >> 12544663

Kinetic studies of lipoprotein metabolism in the metabolic syndrome including effects of nutritional interventions.

P Hugh R Barrett1, Gerald F Watts.   

Abstract

Nutritional interventions may favourably regulate dyslipoproteinemia and, hence, decrease cardiovascular disease risk. Lipoprotein kinetic studies afford a powerful approach to understanding and defining the mechanisms by which such interventions modulate lipoprotein metabolism. Stable isotope tracers and compartment models are now commonly employed for such studies. We review the recent application of tracer methodologies to the study of dyslipoproteinemia in the metabolic syndrome. We also focus on the effects of nutritional intervention studies that have addressed the effects of weight loss, n-3 fatty acids, plant sterols and alcohol on very low density lipoprotein, LDL and HDL metabolism. The potential for statin treatment as an adjunct to dietary modification is also discussed. New tracer methodologies are discussed, specifically those referring to reverse cholesterol transport. The nutritional interventions discussed in this review are readily transferable into clinical preventive practice. The potential benefits to be gained by weight loss and fish oil supplementation in the metabolic syndrome extend beyond their specific and positive effects on lipoprotein metabolism. Furthermore, recent developments in tracer methodologies afford new tools for probing the in-vivo pathways of lipoprotein metabolism in future studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12544663     DOI: 10.1097/00041433-200302000-00011

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  9 in total

Review 1.  Does sustained weight loss reverse the metabolic syndrome?

Authors:  Annie Ferland; Robert H Eckel
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

2.  Linkage between C-reactive protein and triglyceride-rich lipoprotein metabolism.

Authors:  Nuntakorn Thongtang; Margaret R Diffenderfer; Esther M M Ooi; Bela F Asztalos; Gregory G Dolnikowski; Stefania Lamon-Fava; Ernst J Schaefer
Journal:  Metabolism       Date:  2012-09-25       Impact factor: 8.694

3.  Does genetic variation in the Delta6-desaturase promoter modify the association between alpha-linolenic acid and the prevalence of metabolic syndrome?

Authors:  Hong Truong; Julia R DiBello; Edward Ruiz-Narvaez; Peter Kraft; Hannia Campos; Ana Baylin
Journal:  Am J Clin Nutr       Date:  2009-01-14       Impact factor: 7.045

4.  Multiplexed peptide analysis for kinetic measurements of major human apolipoproteins by LC/MS/MS.

Authors:  Mikaël Croyal; Fanta Fall; Véronique Ferchaud-Roucher; Maud Chétiveaux; Yassine Zaïr; Khadija Ouguerram; Michel Krempf; Estelle Nobécourt
Journal:  J Lipid Res       Date:  2016-01-15       Impact factor: 5.922

5.  Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.

Authors:  Dick C Chan; P Hugh R Barrett; Gerald F Watts
Journal:  Clin Biochem Rev       Date:  2004-02

6.  Stable isotope labeling tandem mass spectrometry (SILT): integration with peptide identification and extension to data-dependent scans.

Authors:  Donald L Elbert; Kwasi G Mawuenyega; Evan A Scott; Kristin R Wildsmith; Randall J Bateman
Journal:  J Proteome Res       Date:  2008-09-06       Impact factor: 4.466

7.  Using mass measurements in tracer studies--a systematic approach to efficient modeling.

Authors:  Rajasekhar Ramakrishnan; Janak D Ramakrishnan
Journal:  Metabolism       Date:  2008-08       Impact factor: 8.694

8.  Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study).

Authors:  Carlos A Aguilar-Salinas; Andréia Assis-Luores-Vale; Benjamín Stockins; Hector Mario Rengifo; José Dondici Filho; Abrahão Afiune Neto; Lísia Marcílio Rabelo; Kerginaldo Paulo Torres; José Egídio Paulo de Oliveira; Carlos Alberto Machado; Eliana Reyes; Victor Saavedra; Fernando Florenzano; Ma Victoria Hernández; Sergio Hernandez Jiménez; Erika Ramírez; Cuauhtémoc Vazquez; Saul Salinas; Ismael Hernández; Octavio Medel; Ricardo Moreno; Paula Lugo; Ricardo Alvarado; Roopa Mehta; Victor Gutierrez; Francisco J Gómez Pérez
Journal:  Cardiovasc Diabetol       Date:  2004-07-23       Impact factor: 9.951

Review 9.  Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target.

Authors:  Michel R Hoenig
Journal:  Vasc Health Risk Manag       Date:  2008
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.